Policies meant to protect investors have had the unintended consequence of concentrating the gains of private asset classes—including venture capital—in wealthy areas.

Over the past five years, dilution levels have declined at every stage of startup life. This can have compounding effects for the makeup of company cap tables.

Initial data from Q2 2024 shows modest increases in median valuation and round size across much of the U.S. venture ecosystem.

In a tight market for primary venture fundraising, a historically high number of startups are turning to bridge rounds.

IPOs are the lifeblood of venture capital, but they've been few and far between in recent years. Investors are watching to see if the success of some recent high-profile listings will provide a much-needed spark.

Health and biotech VC fundraising surged in the aftermath of the COVID-19 pandemic and has stood strong against market headwinds.